Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:


Last Updated: August 10, 2022

Details for Patent: 7,176,220

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,176,220 protect, and when does it expire?

Patent 7,176,220 protects GENVOYA, STRIBILD, and VITEKTA, and is included in three NDAs.

Protection for GENVOYA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-three patent family members in thirty-one countries.

Summary for Patent: 7,176,220
Title:4-oxoquinoline compound and use thereof as pharmaceutical agent
Abstract: An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] ##STR00001## wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.
Inventor(s): Satoh; Motohide (Takatsuki, JP), Kawakami; Hiroshi (Takatsuki, JP), Itoh; Yoshiharu (Takatsuki, JP), Shinkai; Hisashi (Takatsuki, JP), Motomura; Takahisa (Takatsuki, JP), Aramaki; Hisateru (Takatsuki, JP), Matsuzaki; Yuji (Takatsuki, JP), Watanabe; Wataru (Takatsuki, JP), Wamaki; Shuichi (Takatsuki, JP)
Assignee: Japan Tobacco Inc. (Tokyo, JP)
Application Number:10/492,833
Patent Claim Types:
see list of patent claims
Use; Compound; Composition;

Drugs Protected by US Patent 7,176,220

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc GENVOYA cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 207561-001 Nov 5, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Gilead Sciences Inc STRIBILD cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 203100-001 Aug 27, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Gilead Sciences Inc VITEKTA elvitegravir TABLET;ORAL 203093-001 Sep 24, 2014 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Gilead Sciences Inc VITEKTA elvitegravir TABLET;ORAL 203093-002 Sep 24, 2014 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,176,220

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2002-336843Nov 20, 2002
Japan2003-065807Mar 11, 2003
Japan2003-139616May 16, 2003
PCT Information
PCT FiledNovember 20, 2003PCT Application Number:PCT/JP03/14773
PCT Publication Date:June 03, 2004PCT Publication Number: WO2004/046115

International Family Members for US Patent 7,176,220

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 042095 See Plans and Pricing
Argentina 087046 See Plans and Pricing
Austria 443048 See Plans and Pricing
Australia 2003302029 See Plans and Pricing
Brazil 0306214 See Plans and Pricing
Brazil PI0306214 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.